Kyorin Pharmaceutical Co (TSE:4569) Cyclically Adjusted Revenue per Share: 円2,066.60 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4569 Kyorin Pharmaceutical Co Ltd TSE:4569
74 GF Score
Price 円1,177.00
GF Value 円1,582.64
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Kyorin Pharmaceutical Co TSE:4569 +0.60% 74 Cyclically Adjusted Revenue per Share is 円2,066.60 as of Mar. 2026. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,582.64 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kyorin Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円588.376. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円2,066.60 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kyorin Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kyorin Pharmaceutical Co was 5.80% per year. The lowest was 3.00% per year. And the median was 4.20% per year.

As of today (2026-07-25), Kyorin Pharmaceutical Co's current stock price is 円1177.00. Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円2,066.60. Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.57.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kyorin Pharmaceutical Co was 1.82. The lowest was 0.53. And the median was 1.08.


Kyorin Pharmaceutical Co  (TSE:4569) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1177.00/2066.60
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kyorin Pharmaceutical Co was 1.82. The lowest was 0.53. And the median was 1.08.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,690.42 1,786.91 1,877.04 2,002.58 2,066.60

Kyorin Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,002.58 2,025.27 2,040.67 2,059.94 2,066.60

TSE:4569 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4569
74GF Score
Kyorin Pharmaceutical Co Ltd TSE:4569
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyorin Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyorin Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=588.376/112.7000*112.7000
=588.376

Current CPI (Mar. 2026) = 112.7000.

Kyorin Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 377.341 98.100 433.500
201609 365.402 98.000 420.212
201612 437.163 98.400 500.694
201703 388.142 98.100 445.908
201706 359.733 98.500 411.593
201709 330.060 98.800 376.496
201712 436.597 99.400 495.015
201803 375.803 99.200 426.946
201806 340.607 99.200 386.960
201809 341.616 99.900 385.387
201812 544.430 99.700 615.419
201903 550.220 99.700 621.964
201906 449.489 99.800 507.589
201909 393.639 100.100 443.188
201912 529.187 100.500 593.427
202003 547.576 100.300 615.272
202006 430.978 99.900 486.198
202009 402.241 99.900 453.779
202012 475.027 99.300 539.129
202103 487.741 99.900 550.234
202106 430.962 99.500 488.135
202109 425.929 100.100 479.542
202112 499.363 100.100 562.220
202203 485.175 101.100 540.843
202206 429.636 101.800 475.638
202209 427.098 103.100 466.867
202212 551.689 104.100 597.266
202303 568.250 104.400 613.427
202306 486.074 105.200 520.728
202309 472.191 106.200 501.092
202312 562.760 106.800 593.849
202403 561.629 107.200 590.444
202406 495.165 108.200 515.759
202409 465.108 108.900 481.338
202412 594.460 110.700 605.200
202503 710.213 111.100 720.441
202506 526.418 111.700 531.131
202509 496.127 112.000 499.228
202512 587.134 113.000 585.575
202603 588.376 112.700 588.376

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円2,066.60 mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Cyclically Adjusted Revenue per Share of 円2,066.60 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kyorin Pharmaceutical Co and its competitors.
Is Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Kyorin Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円2,066.60. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Kyorin Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円2,066.60 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kyorin Pharmaceutical Co and its competitors. Kyorin Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円2,066.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,582.64, compared to a current price of 円1,177.00 — trading 25.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円2,066.60. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Cyclically Adjusted Revenue per Share is 円2,066.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,177.00 is trading 25.6% below its estimated GF Value™ of 円1,582.64. GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4569:

  • Cyclically Adjusted Revenue per Share: 円2,066.60
  • GF Value™: 円1,582.64 vs. price of 円1,177.00 (25.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyorin Pharmaceutical Co Business Description

Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score

Get the complete analysis for TSE:4569

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,177.00
Price
円1,582.64
GF Value